drugset / Trial / NCT05164172
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
RandomizedParallel-groupDouble-blindTreatment
Summary
The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine.
Timeline
- Start
- 2021-12-01
- Primary completion
- 2028-04-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eptinezumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Eptinezumab | Monoclonal antibody | 300 mg | Intravenous |